Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 13/20 | 0.69 |
| ▸ | KCNJ11 | Q14654 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406446 | 1.00 | P2RX7 (0.69) | P2RX7KCNJ11KDM4ELMNAHTT | |
| SCHEMBL4679954 | 0.92 | KCNJ11 (0.59) | P2RX7KCNJ11 | |
| SCHEMBL4679952 | 0.92 | KCNJ11 (0.59) | P2RX7KCNJ11 | |
| SCHEMBL4680236 | 0.91 | P2RX7 (0.58) | P2RX7KCNJ11 | |
| SCHEMBL4680233 | 0.91 | P2RX7 (0.58) | P2RX7KCNJ11 | |
| SCHEMBL4682449 | 0.90 | KCNJ11 (0.69) | P2RX7KCNJ11KDM4E | |
| SCHEMBL4682445 | 0.90 | KCNJ11 (0.69) | P2RX7KCNJ11KDM4E | |
| SCHEMBL4685949 | 0.89 | KCNJ11 (0.57) | P2RX7KCNJ11LMNAHTTSMN1; SMN2 | |
| SCHEMBL4685946 | 0.89 | KCNJ11 (0.57) | P2RX7KCNJ11LMNAHTTSMN1; SMN2 | |
| SCHEMBL6402336 | 0.82 | P2RX7 (0.48) | P2RX7KCNJ11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | ABBOTT LABORATORIES | 2005-08-04 | — | — | US | claimed |
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | ABBOTT LABORATORIES | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | P2RX3, P2RX7, P2RX1 | P2RX7 2/4885KCNJ11 59/4885KDM4E 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.